Solid Minodronic Acid CAS 155648-60-5 Pharmaceutical Intermediates

Product Description:

Product Name: Minodronic Acid CAS NO: 155648-60-5

Synonyms:

(1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid hydrate;

1-Hydroxy-2-[imidazo[1,2-a]pyridin-3-yl]ethylidene-1,1-diphosphonic Acid Monohydrate;

1h-hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid,hydrate;

Chemical & Physical Properties:

Appearance: Solid

Assay :≥99.00%

Exact Mass: 340.022522

Safety Information:

RIDADR: 2811

RTECS: SZ8562470

Hazard Class: 6.1

Packing Group: III

Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis. Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity. The bone resorption inhibitor minodronic acid hydrate was approved and introduced last year in Japan, bringing the total number of bis-phosphonates marketed for this indication to seven. There are an estimated 10 million current and potential osteoporosis sufferers in Japan, a number that is expected to continue growing due to the country’s aging population. Minodronic acid is the first drug to show a significant effect in preventing bone fractures as compared to placebo in a Japanese patient population. Minodronic acid was co-developed by Astellas and Ono, who are marketing the drug as Bonoteo and Recalbon, respectively.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.